QAMINESET
QuicTPD™ Amine Optimization Set
sustainability
Greener Alternative Product
Quality Level
greener alternative category
storage temp.
2-8°C
Related Categories
General description
This set includes 4 representative partial PROTACs, each provided at 5 micromole quantity.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.
Application
The QuicTPD Acid Optimization set is designed to facilitate high throughput synthesis optimization for researchers working with PROTACs.
Features and Benefits
Two of these PROTACs are tailored to target the CRBN E3 ligase, while the other two are directed towards VHL, incorporating both hydrophobic and hydrophilic linkers. By utilizing this optimization set, customers can explore a variety of reaction conditions—up to 24 or more—before proceeding to the complete screening set. This exploration includes testing different coupling reagents, solvents, and bases, allowing for a comprehensive assessment of the synthesis parameters that influence the efficiency and yield of the desired products.
Other Notes
QuicTPD Amine Screening Set
Legal Information
QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2
Target Organs
Blood
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Charles E Hendrick et al.
ACS medicinal chemistry letters, 13(7), 1182-1190 (2022-07-22)
A platform to accelerate optimization of proteolysis targeting chimeras (PROTACs) has been developed using a direct-to-biology (D2B) approach with a focus on linker effects. A large number of linker analogs-with varying length, polarity, and rigidity-were rapidly prepared and characterized in
Ke-Nian Yan et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(26), e2400594-e2400594 (2024-05-01)
Proteolysis targeting chimeras (PROTACs) have emerged as a promising strategy for drug discovery and exploring protein functions, offering a revolutionary therapeutic modality. Currently, the predominant approach to PROTACs discovery mainly relies on an empirical design-synthesis-evaluation process involving numerous cycles of
Rebecca Stevens et al.
Journal of medicinal chemistry, 66(22), 15437-15452 (2023-11-07)
Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that co-opt the cell's natural proteasomal degradation mechanisms to degrade undesired proteins. A challenge associated with PROTACs is the time and resource-intensive optimization; thus, the development of high-throughput platforms for their synthesis and
Zefeng Wang et al.
Nature communications, 14(1), 8437-8437 (2023-12-20)
Thalidomide and its analogs are molecular glues (MGs) that lead to targeted ubiquitination and degradation of key cancer proteins via the cereblon (CRBN) E3 ligase. Here, we develop a direct-to-biology (D2B) approach for accelerated discovery of MGs. In this platform
Articles
Discover QuicTPD™ Acid/Amine Screening Sets for rapid, high-throughput PROTAC® synthesis, streamlining targeted protein degradation research.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service